Evidence map›Paper›PMID 40104011›Full record

ReviewOpen respiratory archives

Effect of Funding Medications for Nicotine Dependence on Tobacco Control: A Narrative Review.

Carlos Rábade-Castedo, António Morais, Sofía Ravara, Jose Ignacio de Granda-Orive, Jose Pedro Boléo-Tomé, Juan Antonio Riesco-Miranda, Angela Ramos Pinedo, Eva de Higes Martinez, Manuel Ángel Martínez Muñiz, Ruth Pitti Pérez and 2 more

Abstract readReview
In one paragraph

Review in Open respiratory archives. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Carlos Rábade-CastedoServicio de Neumología, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
António MoraisDepartamento de Pneumologia, Centro Hospitalar Universitário de São João, EPE, Porto, Portugal.
Sofía RavaraCICS-UBI Health Sciences Research Center, University of Beira Interior and CHCB University Hospital, Covilhã, Portugal.
Jose Ignacio de Granda-OriveServicio de Neumología, Hospital Universitario 12 de Octubre, Madrid, Spain.
Jose Pedro Boléo-ToméHospital Prof. Doutor Fernando Fonseca - Unidade Local de Saúde Amadora-Sintra, Amadora, Portugal.
Juan Antonio Riesco-MirandaServicio Neumologia, Hospital Universitario San Pedro de Alcántara, Cáceres, Spain.
Angela Ramos PinedoServicio de Neumología, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
Eva de Higes MartinezServicio de Neumología, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
Manuel Ángel Martínez MuñizServicio de Neumologia, Hospital San Agustin, Avilés, Asturias, Spain.
Ruth Pitti PérezServicio de Neumología, Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Spain.
Maribel Cristóbal FernándezUnidad Especializada en Tabaquismo. Hospital Clinico Universitario San Carlos, Madrid, Spain.
Carlos A Jiménez-RuizUnidad de Tabaquismo, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacological treatments for smoking associated with psychological counseling triple the chances of quitting. However, the accessibility of these drugs is limited by their financial cost. With this review we aim to demonstrate the effect of partial or full funding in terms of efficacy, effectiveness, cost-effectiveness and quality of life. We conducted a literature search for articles related to the issues mentioned above: analysis of the efficacy, effectiveness and cost-effectiveness of pharmacological treatments for nicotine dependence and the effect of their funding. It is shown that the funding of pharmacological treatment can increase the efficacy and effectiveness of smoking cessation interventions. Such funding increases motivation to make a quit attempt. In addition, these strategies can increase self-efficacy, generate social influence and change attitudes toward quitting. Although the funding of pharmacological treatment benefits all smokers, there are certain populations of smokers who are more sensitive to funding strategies such as social groups with lower incomes and lower educational attainment. These funding strategies for smoking cessation interventions have been shown to improve the health and quality of life of the population, as well as the economy, while reducing tobacco use.

Indexed as

EfficacyFinancingPharmacological treatmentSmoking

Identifiers

PMID40104011
PMCPMC11915161

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.